T. Kalincik Et Al. , "Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis," JAMA Neurology , vol.80, no.7, pp.702-713, 2023
Kalincik, T. Et Al. 2023. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis. JAMA Neurology , vol.80, no.7 , 702-713.
Kalincik, T., Sharmin, S., Roos, I., Freedman, M. S., Atkins, H., Burman, J., ... Massey, J.(2023). Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis. JAMA Neurology , vol.80, no.7, 702-713.
Kalincik, Tomas Et Al. "Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis," JAMA Neurology , vol.80, no.7, 702-713, 2023
Kalincik, Tomas Et Al. "Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis." JAMA Neurology , vol.80, no.7, pp.702-713, 2023
Kalincik, T. Et Al. (2023) . "Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis." JAMA Neurology , vol.80, no.7, pp.702-713.
@article{article, author={Tomas Kalincik Et Al. }, title={Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis}, journal={JAMA Neurology}, year=2023, pages={702-713} }